Report Overview:
Pharmacogenomics (PGx) is a branch of precision medicine that studies how an individual’s genetic makeup affects their response to drugs. It combines pharmacology (the science of drugs) and genomics (the study of genes and their functions) to tailor drug treatments for individual patients, improving efficacy and reducing adverse effects. By analyzing genetic variations, pharmacogenomics helps in developing personalized treatment plans, minimizing trial-and-error prescriptions, and optimizing drug dosages.
Market Value:
The global Pharmacogenomics (PGx) market is projected to grow from US$ 8,569.5 million in 2024 to US$ 14,590 million by 2030, reflecting a CAGR of 9.3% during the forecast period.
CAGR of 9.3% (2024 – 2032)
By Applications:
Cardiovascular Diseases (CVD)
Central Nervous System (CNS) Disorders
Cancer/Oncology
By Types:
• Polymerase Chain Reaction (PCR)
• Microarray
• Sequencing
Key players include:
• Abbott Laboratories
• Affymetrix, Inc.
• Assurex Health, Inc
• AstraZeneca
• GeneDX
• Illumina, Inc.
